Inovio Pharmaceuticals, Inc. (INO)
After hours:
| Previous close | 9.68 |
| Open | 9.77 |
| Bid | 9.92 x 100 |
| Ask | 10.06 x 400 |
| Day's range | 9.28 - 10.24 |
| 52-week range | 3.84 - 14.75 |
| Volume | |
| Avg. volume | 496,894 |
| Market cap | 259.584M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.09 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.25 |
PR NewswireINOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case befor
PR NewswireINOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
ZacksDoes Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
